Cipher Pharmaceuticals (CPH) Reaches New 1-Year Low at $3.76
Cipher Pharmaceuticals Inc (TSE:CPH) (NASDAQ:CPHR) shares reached a new 52-week low on Monday . The stock traded as low as C$3.76 and last traded at C$4.01, with a volume of 3775 shares changing hands. The stock had previously closed at C$4.05.
Separately, TD Securities reduced their target price on shares of Cipher Pharmaceuticals from C$6.50 to C$5.00 and set a “hold” rating for the company in a report on Tuesday, November 7th.
The stock has a market cap of $107.69, a PE ratio of -19.29 and a beta of 1.26.
In other news, Director Harold Morton Wolkin purchased 35,000 shares of the company’s stock in a transaction on Friday, November 10th. The shares were purchased at an average cost of C$4.69 per share, with a total value of C$164,150.00.
About Cipher Pharmaceuticals
Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical dermatology company in South America, Canada, and the United States. It offers CIP-ISOTRETINOIN, a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; CIP-FENOFIBRATE, a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CIP-TRAMADOL ER, a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.
Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.